Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.78 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498070 | 0.88 | NR4A2 (1.00) | NR4A2CREBBPGABRA1GABRB1GABRA3 | |
| SCHEMBL31435646 | 0.88 | NR4A2 (1.00) | NR4A2CREBBPGABRA1GABRB1GABRA3 | |
| SCHEMBL6029933 | 0.85 | NR4A2 (0.57) | NR4A2CREBBPGABRA1GABRB1GABRA3 | |
| SCHEMBL6490095 | 0.84 | GABRA1 (0.70) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL31618837 | 0.84 | NR4A2 (0.56) | NR4A2CREBBPGABRA1GABRB1GABRA3 | |
| SCHEMBL2434449 | 0.83 | NR4A2 (0.72) | NR4A2CREBBPNPC1MAPTMAP2K1 | |
| SCHEMBL6588128 | 0.83 | NR4A2 (1.00) | NR4A2CREBBPNPC1MAPTMAP2K1 | |
| SCHEMBL6418495 | 0.83 | NR4A2 (0.72) | NR4A2CREBBPNPC1MAPTTUBB1 | |
| SCHEMBL31048762 | 0.83 | NR4A2 (0.72) | NR4A2CREBBPNPC1MAPTMAP2K1 | |
| SCHEMBL17023350 | 0.82 | PBRM1 (0.59) | NR4A2GABRA1GABRB1GABRA3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4695240-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025151602-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024215923-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-117756785-A | Preparation and application of N- (pyridine-2-yl) benzo [ b ] five-membered heterocycle-3-carboxamide structure compound | 江西中医药大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| CN-111278821-B | Spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-115850152-A | Preparation method and application of impurity A-7-imp3 | 河北鼎泰制药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-101374834-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | NR4A2 23/4885CREBBP 440/4885CHEK1 3368/4885 |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | NR4A2 1079/4885CREBBP 1790/4885CHEK1 4616/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | NR4A2 57/4885CREBBP 336/4885CHEK1 1854/4885 |
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | NR4A2 179/4885CREBBP 1385/4885CHEK1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.